news
Radioligand therapy demonstrates novel first line benefit
Novartis’ radioligand therapy (RLT) is the first to demonstrate clinically meaningful benefit in a first line setting.
List view / Grid view
radiotherapy
news
Radiation with immunotherapy increases lung cancer survival
Phase I study analysis determined immunotherapy with radiation is more effective than radiotherapy alone for metastatic non-small cell lung cancer.
news
Production of Novartis’ radioligand therapy suspended
Novartis has suspended production at its radioligand therapy production sites in Ivrea, Italy and Millburn, New Jersey as it addresses potential quality issues identified in its manufacturing processes.
news
Novel radionuclide therapy found to be more effective in NET patients
The study shows modifying the standard of care for late-stage neuroendocrine tumours (NETs) with Evans blue dye makes the treatment more effective and potentially less toxic.
news
Trial results show compound makes radiotherapy more effective
A trial has shown that radiotherapy is more effective when levels of ropidoxuridine in a patients' body reach a certain level...
news
Prostate cancer treatment reduced from 37 treatments to 5
A minimally invasive hydrogel technology was administered, and has previously shown to decrease treatment side effects...
